OlympiAD trial: moving to a next level of treatment for patients with BRCA mutation and her2-negative metastatic breast cancer

Ann Palliat Med. 2020 Mar;9(2):510-511. doi: 10.21037/apm.2020.01.14. Epub 2020 Feb 16.
No abstract available

Publication types

  • Editorial

MeSH terms

  • Antineoplastic Agents / therapeutic use*
  • BRCA2 Protein / metabolism*
  • Breast Neoplasms / drug therapy*
  • Breast Neoplasms / metabolism*
  • Female
  • Humans
  • Neoplasm Recurrence, Local / drug therapy
  • Neoplasm Recurrence, Local / metabolism
  • Phthalazines / therapeutic use*
  • Piperazines / therapeutic use*

Substances

  • Antineoplastic Agents
  • BRCA2 Protein
  • BRCA2 protein, human
  • Phthalazines
  • Piperazines
  • olaparib